Alpha 7 Nicotinic Acetylcholine Receptor Agonist PHA 568487 Reduces Acute Inflammation but Does Not Affect Cardiac Function or Myocardial Infarct Size in the Permanent Occlusion Model

Filip Mjörnstedt,Azra Miljanovic,Rebecka Wilhelmsson,Malin Levin,Maria E. Johansson
DOI: https://doi.org/10.3390/ijms25084414
IF: 5.6
2024-04-18
International Journal of Molecular Sciences
Abstract:Stimulation of the alpha 7 nicotinic acetylcholine receptor (α7nAChR) has shown beneficial effects in several acute inflammatory disease models. This study aims to examine whether treatment with the selective α7nAChR agonist PHA 568487 can dampen inflammation and thereby improve cardiac function after myocardial infarction in mice. The possible anti-inflammatory properties of α7nAChR agonist PHA 568487 were tested in vivo using the air pouch model and in a permanent occlusion model of acute myocardial infarction in mice. Hematologic parameters and cytokine levels were determined. Infarct size and cardiac function were assessed via echocardiography 24 h and one week after the infarction. Treatment with α7nAChR agonist PHA 568487 decreased 12 (CCL27, CXCL5, IL6, CXCL10, CXCL11, CXCL1, CCL2, MIP1a, MIP2, CXCL16, CXCL12 and CCL25) out of 33 cytokines in the air pouch model of acute inflammation. However, α7nAChR agonist PHA 568487 did not alter infarct size, ejection fraction, cardiac output or stroke volume at 24 h or at 7 days after the myocardial infarction compared with control mice. In conclusion, despite promising immunomodulatory effects in the acute inflammatory air pouch model, α7nAChR agonist PHA 568487 did not affect infarct size or cardiac function after a permanent occlusion model of acute myocardial infarction in mice. Consequently, this study does not strengthen the hypothesis that stimulation of the α7nAChR is a future treatment strategy for acute myocardial infarction when reperfusion is lacking. However, whether other agonists of the α7nAChR can have different effects remains to be investigated.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
This paper aims to explore whether the α7 nicotinic acetylcholine receptor (α7nAChR) agonist PHA 568487 can alleviate acute inflammation and thereby improve cardiac function after myocardial infarction in mice. Specifically, the study tests the potential anti-inflammatory effects of PHA 568487 and its impact on cardiac function using an acute inflammation air pouch model and a permanent occlusion myocardial infarction model. In the acute inflammation air pouch model, PHA 568487 significantly reduced the concentrations of 12 cytokines, demonstrating a notable anti-inflammatory effect. However, in the permanent occlusion myocardial infarction model, PHA 568487 did not alter indicators such as infarct size, ejection fraction, cardiac output, or left ventricular mass. Therefore, despite the significant immunomodulatory effects of PHA 568487 in the acute inflammation model, it did not improve cardiac function or reduce infarct size in the permanent occlusion myocardial infarction model. This suggests that the α7nAChR agonist PHA 568487 may not be an effective strategy for treating acute myocardial infarction, especially in the absence of reperfusion. Nonetheless, the effects of other α7nAChR agonists remain to be further investigated.